MEI Pharma conducted a private investment of 100 million USD and became the first public company to use Litecoin as a treasury reserve asset.
MEI Pharma establishes a new treasury strategy that combines biotechnology and blockchain with the participation of Charlie Lee, the founder of Litecoin, while partnering with GSR as a digital asset advisor.
MAIN CONTENT
MEI Pharma raised 100 million USD at a price of 3.42 USD per share in a private investment round.
MEI is the first public company to hold Litecoin as a treasury reserve asset, expanding the application of cryptocurrency in traditional business.
Charlie Lee joins the board of MEI Pharma and GSR supports digital asset strategy consulting.
What has MEI Pharma done to integrate Litecoin into its financial strategy?
MEI Pharma announced a private funding round of 100 million USD, which included prominent funds such as the Litecoin Foundation and many leading cryptocurrency organizations. The company became the first public organization to use Litecoin as its primary treasury reserve asset. This is a breakthrough that brings cryptocurrency into the practical financial strategy of a biotechnology-focused enterprise.
"MEI's choice of Litecoin as a reserve asset not only demonstrates the growing trust of institutions in LTC but also promotes broader adoption in traditional capital markets."
Charlie Lee, Founder of Litecoin, 2025
Litecoin is regarded as a stable, fast, and low-cost cryptocurrency network, executing millions of global transactions through prominent payment platforms like BitPay. The partnership with GSR strengthens Litecoin's position in the institutional DeFi space.
What is the significance of being the first public company to use Litecoin as a treasury asset?
MEI Pharma's adoption of Litecoin as a reserve asset for the first time in a public company has significant strategic implications. It reflects a shift from perceiving cryptocurrency as a speculative tool to a strategic asset with practical use, especially in payments and remittances.
"Litecoin has maintained stability and accessibility over the past 14 years, leading globally in transactions on digital payment platforms."
Charlie Lee, Founder of Litecoin, 2025
This strategy is a testament to the belief in the future of Litecoin as a widely used cryptocurrency in real commerce, rather than merely a tool for storing digital value.
What is the timeline for completion and the proposed use of funds from this fundraising round?
MEI Pharma is expected to finalize a private investment deal worth 100 million USD on July 22, 2025, subject to final approvals. The entire amount will be used to purchase Litecoin, making LTC the company's primary treasury asset.
At the same time, MEI ensures that the investment complies with Nasdaq's listing standards and floor prices, and will file a registration statement with the U.S. Securities and Exchange Commission (SEC) after the transaction is completed.
What impact does the investment news have on MEI Pharma's stock?
Following the investment announcement, MEI Pharma's shares had a pre-market trading increase of 83%. The stock peaked at 9 USD before adjusting and is currently trading around 5.91 USD, up 31% in the last 24 hours. This indicates market positivity and expectations regarding the strategy of integrating cryptocurrency into asset management.
Frequently Asked Questions
How did MEI Pharma raise funds?
MEI Pharma raised 100 million USD through a private offering at a price of 3.42 USD per share, with the participation of many reputable cryptocurrency funds.
Why did MEI choose Litecoin as a reserve asset?
Litecoin is considered a fast, stable, and low-cost cryptocurrency with a 14-year development history, suitable for MEI Pharma's practical treasury strategy.
What is Charlie Lee's role in MEI Pharma?
Charlie Lee, the founder of Litecoin, joins the board of MEI Pharma to support the strategy of integrating blockchain technology and biotechnology.
How does GSR contribute to the project?
GSR was appointed as a digital asset and treasury advisor, assisting MEI Pharma in implementing an in-depth Litecoin Treasury strategy.
What are the plans for the funds after the successful fundraising?
The entire 100 million USD will be used to purchase Litecoin, strengthening the treasury reserve and enhancing MEI Pharma's digital asset growth strategy.
Source: https://tintucbitcoin.com/litecoin-cong-khai-kho-bac-100-trieu-usd/
Thank you for reading this article!
Please Like, Comment, and Follow TinTucBitcoin to stay updated with the latest news about the cryptocurrency market and not miss any important information!
